Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06315751 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome
A Phase 2 study of Tourette Syndrome, sponsored by Noema Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
- 20
- Study locations
NCT06315751 is a Phase 2 study of Tourette Syndrome that is active but no longer recruiting, run by Noema Pharma. The registered enrollment target is 164 participants, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (100% higher). The trial reports 20 study locations across 9 states.
The verdict
NCT06315751, a Phase 2 study of Tourette Syndrome, is active but no longer recruiting, sponsored by Noema Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Gemlapodect
Study Locations (20)
Florida
- Noema TTS-201 Site #54 - Gulf Breeze
- Noema TTS-201 Site #05 - Hialeah
- Noema TTS-201 Site #97 - Jensen Beach
- Noema TTS-201 Site #71 - Largo
- Noema TTS-201 Site #44 - Maitland
- Noema TTS-201 Site # 74 - Miami
- Noema TTS-201 Site #56 - Miami Lakes
- Noema TTS-201 Site #61 - Orlando
California
- Noema TTS-201 Site #95 - Bellflower
- Noema TTS-201 Site #75 - Glendale
- Noema TTS-201 Site #59 - San Rafael
- Noema TTS-201 Site #21 - Walnut Creek
Georgia
- Noema TTS-201 Site #79 - Atlanta
- Noema TTS-201 Site #87 - Peachtree Corners
Arizona
- Noema TTS-201 Site #81 - Sun City
Massachusetts
- Noema TTS-201 Site #55 - Boston
Michigan
- Noema TTS-201 Site #51 - Ann Arbor
Missouri
- Noema TTS-201 Site #96 - Saint Charles
Nebraska
- Noema TTS-201 Site #93 - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2024-09-10 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06315751
The ClinicalTrials.gov registry entry for NCT06315751 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 82-participant average among 33 other Tourette Syndrome trials with a reported enrollment target (100% higher). The listed sponsor is Noema Pharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tourette Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06315751 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06315751 about?
NCT06315751 is a clinical study titled "Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome". This study is designed to evaluate the efficacy and safety of gemlapodect (NOE-105) on reducing tics associated with Tourette Syndrome (TS) in adults with TS. Adolescents will be enrolled after a sentinel cohort of adults is complete.
What is the current status of trial NCT06315751?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2024-09-10. Estimated completion is 2026-06.
What conditions does trial NCT06315751 study?
This clinical trial studies the following conditions: Tourette Syndrome.
What interventions are being tested in trial NCT06315751?
The interventions under investigation include: Placebo (DRUG), Gemlapodect (DRUG).
Who is sponsoring clinical trial NCT06315751?
This trial is sponsored by Noema Pharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06315751 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tourette Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multimodal Profiling of Response to Pediatric Comprehensive Behavioral Intervention for Tics
RECRUITING · Phase 2
-
CBIT+TMS R33 Phase
RECRUITING · Phase 2
-
Pramipexole Pilot Phase II Study in Children and Adolescents With Tourette Disorder According to DSM-IV Criteria
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation (TMS) for Individuals With Tourette's Syndrome
COMPLETED · Phase 2
-
Cognitive Behavior Therapy and Habit Reversal Training for the Treatment of Chronic Tic Disorders in Children
COMPLETED · Phase 2
-
Sensorimotor and Psychosocial Trajectories in Adolescents With Tic Disorder
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.